Virtus Fund Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Virtus Fund Advisers’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$394K	Buy	+13,917	New	+$388K	﹤0.01%	357

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Virtus Fund Advisers's RETA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2017: 13,917 shares worth $394K. The stake represents ﹤0.01% of the portfolio and ranks #357 among its holdings.

89 funds tracked by Wall St. Rank hold RETA as of Q4 2017.

Virtus Fund Advisers held 13,917 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $394K as of Q4 2017.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Virtus Fund Advisers position in Q4 2017.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #357 holding.
89 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.